Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
10.25 SEK | 0.00% |
|
+1.49% | -8.65% |
May. 08 | Boule Diagnostics AB Appoints Rikke Rytter as Director | CI |
May. 07 | Transcript : Boule Diagnostics AB, Q1 2024 Earnings Call, May 07, 2024 |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- With a P/E ratio at 10.66 for the current year and 9.14 for next year, earnings multiples are highly attractive compared with competitors.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The company appears to be poorly valued given its net asset value.
- For the past twelve months, EPS forecast has been revised upwards.
Weaknesses
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.65% | 37.67M | B- | ||
+0.20% | 203B | B | ||
+3.65% | 178B | B- | ||
+31.11% | 157B | B- | ||
+32.35% | 112B | A- | ||
+1.94% | 64.58B | A- | ||
+22.60% | 56.33B | B+ | ||
-3.27% | 46.75B | B+ | ||
-9.79% | 36.59B | A | ||
-0.58% | 35.09B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BOUL Stock
- Ratings Boule Diagnostics AB